Pipeline of Epigenetic Programs
Our pipeline is led by tazemetostat, an internally developed first-in-class EZH2 inhibitor, which is being evaluated in a robust clinical program that includes global clinical trials in patients with relapsed or refractory non-Hodgkin lymphoma (NHL), in adult and pediatric patients with certain genetically defined solid tumors and in patients with mesothelioma. Tazemetostat is also being evaluated in a front-line combination study with R-CHOP, a prednisolone combination and an immuno-oncology combination study with Tecentriq™ (atezolizumab) in patients with diffuse large B-cell lymphoma, the most common form of NHL. We have also initiated an immune-oncology combination study with Tecentriq™ in NSCLC.
In addition, pinometostat, a clinical-stage DOT1L inhibitor, is being evaluated in a collaboration with Celgene for the treatment of pediatric MLL-r, a form of acute leukemia.
We are advancing discovery-stage wholly owned small molecule programs against novel HMT, HAT and helicase targets. By 2020, we plan to have advanced at least three new programs into clinical development. Most recently, we are advancing the first of these, our novel G9a inhibitor drug candidate, EZM8266, toward clinical initiation. EZM8266 will be studied as a potential treatment for sickle cell disease.
Under collaboration agreements with Celgene and GlaxoSmithKline, we have developed additional small molecule oncology programs, including a potential first-in-class PRMT5 inhibitor with GlaxoSmithKline.